Computational drug repositioning and wet-lab validation approach identifies polo-like kinase inhibitors as potential therapeutics for pulmonary fibrosis
T. Imakura (Tokushima, Japan), S. Sato (Tokushima, Japan), K. Koyama (Tokushima, Japan), H. Ogawa (Tokushima, Japan), T. Niimura (Tokushima, Japan), K. Murakami (Tokushima, Japan), Y. Yamashita (Tokushima, Japan), K. Haji (Tokushima, Japan), N. Naito (Tokushima, Japan), K. Kagawa (Tokushima, Japan), H. Kawano (Tokushima, Japan), Y. Zamami (Tokushima, Japan), K. Ishizawa (Tokushima, Japan), Y. Nishioka (Tokushima, Japan)
Source: International Congress 2022 – New mechanistic insights into acute and chronic interstitial lung disorders
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Imakura (Tokushima, Japan), S. Sato (Tokushima, Japan), K. Koyama (Tokushima, Japan), H. Ogawa (Tokushima, Japan), T. Niimura (Tokushima, Japan), K. Murakami (Tokushima, Japan), Y. Yamashita (Tokushima, Japan), K. Haji (Tokushima, Japan), N. Naito (Tokushima, Japan), K. Kagawa (Tokushima, Japan), H. Kawano (Tokushima, Japan), Y. Zamami (Tokushima, Japan), K. Ishizawa (Tokushima, Japan), Y. Nishioka (Tokushima, Japan). Computational drug repositioning and wet-lab validation approach identifies polo-like kinase inhibitors as potential therapeutics for pulmonary fibrosis. 2791
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|